Document:

EX-4.2

 Exhibit 4.2 

NEITHER THE SECURITY REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY JURISDICTION. THIS SECURITY AND THE SECURITIES ISSUABLE UPON ITS EXERCISE MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, ASSIGNED, ENCUMBERED, HYPOTHECATED OR
OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (I) A REGISTRATION STATEMENT WITH RESPECT TO SUCH SECURITIES THAT IS EFFECTIVE UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAW, OR (II) ANY EXEMPTION FROM REGISTRATION UNDER SUCH ACT, OR APPLICABLE
STATE SECURITIES LAW, RELATING TO THE DISPOSITION OF SECURITIES, INCLUDING RULE 144, AND, IF REQUESTED BY THE COMPANY, AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY OPINING AS TO SUCH EXEMPTION. 

THIS SECURITY IS SUBJECT TO THE PROVISIONS OF THE WARRANT AGREEMENT, DATED AS OF MARCH 26, 2007, BETWEEN THE COMPANY AND BAYER SCHERING PHARMA
AG. A COPY OF SUCH WARRANT AGREEMENT IS AVAILABLE AT THE OFFICES OF THE COMPANY. 
  

			
	No.     	  	Exercise Percentage             

 SYNDAX PHARMACEUTICALS, INC. 

WARRANT CERTIFICATE 
 THIS
CERTIFIES that Bayer Schering Pharma AG or its registered assigns is the registered holder (the “Registered Holder”) of a Warrant representing the right to purchase the number, as determined below, of fully paid and nonassessable
shares of common stock, par value $0.0001 per share (the “Common Stock”), of Syndax Pharmaceuticals, Inc. (the “Company”), a corporation organized under the laws of the State of Delaware at the Exercise Price at the
times specified in the Warrant Agreement (as hereinafter defined), by surrendering this Warrant Certificate, with the form of Election to Purchase attached hereto duly executed together with the Investment Representation Statement annexed to the
Warrant Agreement as Exhibit B and by paying in full the Exercise Price for the number of shares of Common Stock equal to the Exercise Amount. Payment of the Exercise Price shall be made as set forth in the Warrant Agreement. Upon initial
issuance this Warrant Certificate represents the right to acquire, upon exercise in full, such number of shares of Common Stock as is issuable upon an exercise of the Warrant as to the Exercise Percentage specified herein.1 
  

	1 	(i) In the case of a Warrant Certificate issued after a partial exercise, replace the Exercise Percentage specified herein with the amount equal to the Exercise Percentage specified herein minus the Exercise
Percentage being exercised; (ii) in the case of Warrant Certificates issued on transfer, (x) use the transferred Exercise Percentage for the transferee and (y) replace the Exercise Percentage specified herein with the remaining
Exercise Percentage for the transferor and (iii) in the case of Warrant Certificates issued after a transfer and a subsequent partial exercise, replace the Exercise Percentage specified herein with the Exercise Percentage of the Warrant
Certificate immediately after the transfer reduced by the percentage of the Exercise Percentage exercised in the partial exercise. 

  
 1 

 No Warrant may be exercised after the Expiration Date. The Warrant evidenced hereby shall
thereafter become void, subject to the terms of the Warrant Agreement. 
 Prior to the Expiration Date, subject to Section 3.05 of the
Warrant Agreement and any applicable laws, rules or regulations restricting transferability and to any restriction on transferability that may appear on this Warrant Certificate and in accordance with the terms of the Warrant Agreement, the
Registered Holder shall be entitled to transfer this Warrant Certificate, in whole or in part, upon surrender of this Warrant Certificate at the principal office of the Company with the form of assignment set forth hereon duly executed;
provided that, (i) for transfers made to a Person other than an Affiliate, written notice is given to the Company at least 10 Business Days before the transfer and the transferor shall provide, at the Company’s request, an opinion
of counsel reasonably satisfactory to the Company that such transfer does not require registration under the Securities Act, (ii) the transfer shall be for a portion of this Warrant Certificate not less than the Minimum Exercise Threshold,
(iii) the Holder shall provide written notice to the Company of any transfer to an Affiliate within 10 Business Days after the transfer, and (iv) the transferee shall agree to be bound by the terms of this Agreement; provided
further that for purposes of this proviso, Affiliate shall not include any Person which is an individual. Written notice given under this paragraph shall include without limitation the name of the transferee, the Exercise Percentage transferred
to such transferee, the date of the transfer and the transferee’s address for notice purposes. Upon any such transfer, a new Warrant Certificate or Warrant Certificates will be issued to (x) the transferee representing a Warrant for the
Exercise Percentage specified in the foregoing written notice in accordance with instructions in the form of assignment and (y) the transferor representing a Warrant for the remaining Exercise Percentage not transferred, if any. 

Upon the exercise of a Warrant for less than all of the Exercise Percentage evidenced by this Warrant Certificate, there shall be issued to
the Registered Holder a new Warrant Certificate in respect of the portion of the Exercise Percentage not exercised. 
 Prior to the
Expiration Date, the Registered Holder shall be entitled to exchange this Warrant Certificate, with or without other Warrant Certificates, for another Warrant Certificate or Warrant Certificates for a Warrant or Warrants for the same aggregate
Exercise Percentage upon surrender of this Warrant Certificate at the principal office of the Company, subject to the terms of the Warrant Agreement. 

Upon certain events provided for in the Warrant Agreement, the Exercise Price and the shares of Common Stock issuable upon the exercise of
each Warrant shall be adjusted as provided in the Warrant Agreement. 
 This Warrant Certificate is issued under and in accordance with the
Warrant Agreement dated as of March 26, 2007 (the “Warrant Agreement”), between the Company and Bayer Schering Pharma AG and is subject to the terms and provisions contained in the Warrant Agreement. All capitalized terms not
defined herein shall have the meanings given such terms as set forth in the Warrant Agreement. 
 This Warrant Certificate shall not entitle
the Registered Holder to any of the rights of a stockholder of the Company, including, without limitation, the right to vote, to receive dividends 

  
 2 

 
and other distributions, or to attend or receive any notice of meetings of stockholders or any other proceedings of the Company. 

IN WITNESS WHEREOF, the Company has caused this Warrant Certificate to be duly executed as of the date set forth below. 

Date: 
  

					
	SYNDAX PHARMACEUTICALS, INC.
			
		 	By:	 	  

		 		 	Name:
		 		 	Title:

  
 3 

 [Form of Assignment] 

FOR VALUE RECEIVED, the undersigned hereby irrevocably sells, assigns and transfers unto the Assignee named below all of the rights of the
undersigned represented by the within Warrant Certificate, with respect to the number of Warrant Shares issuable upon exercise of the Warrant for the Exercise Percentage set forth below: 

 

					
	Name of Assignee	  	Address	  	Exercise Percentage
		  		  	
		  		  	
		  		  	

 and does hereby irrevocably constitute and appoint true and lawful Attorney, to make such transfer on the books of Syndax
Pharmaceuticals, Inc. maintained for that purpose, with full power of substitution in the premises. 
  

			
	Date:	 	  

 
					
		
		 	  

		 	Signature
		
		 	(Signature must confirm in all respects to the name of holder as specified on the face of the Warrant Certificate.

  
 4 

 [Form of Election to Purchase] 

The undersigned hereby irrevocably elects to exercise the Warrant represented by this Warrant Certificate as to an Exercise Percentage of
    %2, which represents an Exercise Amount of             3
shares of Common Stock of Syndax Pharmaceuticals, Inc. (the “Company”), based on the number of shares of Common Stock outstanding on a Fully Diluted Basis equal to
            4 shares, and requests that certificates for such shares be issued and delivered as follows: 

 

			
	ISSUE TO:	 	  

	(NAME)

			
	
	  

	(ADDRESS, INCLUDING ZIP CODE)
	
	  

	(SOCIAL SECURITY OR OTHER IDENTIFICATION NUMBER)

			
		
	DELIVER TO:	 	  

	(NAME)

  

			
	at	 	  

	(ADDRESS, INCLUDING ZIP CODE)

 In full payment of the purchase price with respect to the exercise of Warrants, the undersigned: 

 

	 	 ̈	hereby tenders payment of $         by cash, certified check, cashier’s check or money order payable in United States currency to the order of the Company; or

  

	 	 ̈	hereby delivers to the Company for cancellation the portion of the Warrant representing that number of Warrant Shares otherwise issuable to the holder, such that the excess of the aggregate current Fair Market Value of
such specified number of Warrant Shares on the Date of Exercise over the portion of the Exercise Price attributable to such specified number of Warrant Shares shall equal the aggregate Exercise Price attributable to the Warrant Shares being
purchased. 

  

	2 	Holder shall fill in the applicable permitted Exercise Percentage. 

	3 	The Company shall fill in the Exercise Amount. 

	4 	The Company shall fill in the number of outstanding shares of Common Stock on a Fully Diluted Basis (which shall become fixed on the IPO Date). 

  
 5 

 If the Warrant hereby exercised is less than the whole Warrant represented by this Warrant
Certificate, the undersigned requests that a new Warrant Certificate representing the portion of the Warrant not exercised be issued and delivered as follows: 
  

			
	ISSUE TO:	 	  

	(NAME)

			
	
	  

	(ADDRESS, INCLUDING ZIP CODE)
	
	  

	(SOCIAL SECURITY OR OTHER IDENTIFICATION NUMBER)

			
		
	DELIVER TO:	 	  

	(NAME)

  

			
	at	 	  

	(ADDRESS, INCLUDING ZIP CODE)

 Date:                  ,
         
  

	
	  

	Signature
	
	(Signature must conform in all respects to name of holder as specified on the face of the Warrant Certificate.)
	
	PLEASE INSERT SOCIAL SECURITY OR TAX I.D. NUMBER OF HOLDER
	
	  

  
 6EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 
 SYNDAX
PHARMACEUTICALS, INC. 
 AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
		
	SECTION 1 [INTENTIONALLY OMITTED.]	  	 	1	  
		
	SECTION 2 REGISTRATION RIGHTS; RESTRICTIONS ON TRANSFERABILITY	  	 	2	  
			
	 2.1
	 	 Certain Definitions
	  	 	2	  
			
	 2.2
	 	 Restrictions
	  	 	3	  
			
	 2.3
	 	 Restrictive Legend
	  	 	3	  
			
	 2.4
	 	 Notice of Proposed Transfers
	  	 	4	  
			
	 2.5
	 	 Requested Registration
	  	 	4	  
			
	 2.6
	 	 Company Registration
	  	 	6	  
			
	 2.7
	 	 Registration on Form S-3
	  	 	7	  
			
	 2.8
	 	 Corporate Transaction
	  	 	8	  
			
	 2.9
	 	 Expenses of Registration
	  	 	8	  
			
	 2.10
	 	 Registration Procedures
	  	 	8	  
			
	 2.11
	 	 Indemnification
	  	 	10	  
			
	 2.12
	 	 Information by Holder
	  	 	11	  
			
	 2.13
	 	 Rule 144 Reporting
	  	 	11	  
			
	 2.14
	 	 Transfer of Registration Rights
	  	 	12	  
			
	 2.15
	 	 Market Stand-off Agreement
	  	 	12	  
			
	 2.16
	 	 Termination of Rights
	  	 	13	  
		
	SECTION 3 RIGHT OF FIRST OFFER	  	 	13	  
			
	 3.1
	 	 Right of First Offer
	  	 	13	  
			
	 3.2
	 	 Definition of New Securities
	  	 	13	  
			
	 3.3
	 	 Notice of Right
	  	 	14	  
			
	 3.4
	 	 Exercise of Right
	  	 	15	  
			
	 3.5
	 	 Lapse and Reinstatement of Right
	  	 	15	  
			
	 3.6
	 	 Transfer of Right of First Offer
	  	 	15	  

  
 - i - 

							
	 3.7
	 	 Rights of Affiliated Investors
	  	 	15	  
			
	 3.8
	 	 Termination of Right of First Offer
	  	 	15	  
		
	SECTION 4 [INTENTIONALLY OMITTED]	  	 	16	  
		
	SECTION 5 AFFIRMATIVE COVENANTS OF THE COMPANY	  	 	16	  
			
	 5.1
	 	 Financial Information
	  	 	16	  
			
	 5.2
	 	 Inspection
	  	 	16	  
			
	 5.3
	 	 Confidentiality
	  	 	16	  
			
	 5.4
	 	 Patent, Copyright and Nondisclosure Agreements
	  	 	17	  
			
	 5.5
	 	 Stock Vesting
	  	 	17	  
			
	 5.6
	 	 Qualified Small Business
	  	 	17	  
			
	 5.7
	 	 Insurance
	  	 	18	  
			
	 5.8
	 	 Annual Budget
	  	 	18	  
			
	 5.9
	 	 Board Matters
	  	 	18	  
			
	 5.10
	 	 Management Compensation
	  	 	18	  
			
	 5.11
	 	 Compliance with Laws
	  	 	18	  
			
	 5.12
	 	 Payment of Taxes
	  	 	18	  
			
	 5.13
	 	 Financings
	  	 	18	  
			
	 5.14
	 	 Amended and Restated Voting Agreement
	  	 	19	  
			
	 5.15
	 	 Termination of Covenants
	  	 	19	  
		
	SECTION 6 TRANSFERS OF SECURITIES BY IINVESTORS	  	 	19	  
			
	 6.1
	 	 Notices
	  	 	19	  
			
	 6.2
	 	 Acceptance of Offer
	  	 	19	  
			
	 6.3
	 	 Allocation of Securities and Payment
	  	 	19	  
			
	 6.4
	 	 Failure to Exercise
	  	 	20	  
			
	 6.5
	 	 Assignment
	  	 	20	  
			
	 6.6
	 	 Permitted Transfers
	  	 	20	  
			
	 6.7
	 	 Drag-Along
	  	 	20	  
			
	 6.8
	 	 Termination
	  	 	20	  

  
 - ii - 

							
	SECTION 7 MISCELLANEOUS	  	 	21	  
			
	 7.1
	 	 Successors and Assigns
	  	 	21	  
			
	 7.2
	 	 Third Parties
	  	 	21	  
			
	 7.3
	 	 Governing Law
	  	 	21	  
			
	 7.4
	 	 Counterparts
	  	 	21	  
			
	 7.5
	 	 Notices
	  	 	21	  
			
	 7.6
	 	 Severability
	  	 	21	  
			
	 7.7
	 	 Amendment and Waiver
	  	 	21	  
			
	 7.8
	 	 Rights of Holders
	  	 	21	  
			
	 7.9
	 	 Delays or Omissions
	  	 	22	  
			
	 7.10
	 	 Attorneys’ Fees
	  	 	22	  
			
	 7.11
	 	 Headings
	  	 	22	  
			
	 7.12
	 	 Entire Agreement
	  	 	22	  
			
	 7.13
	 	 Further Assurances
	  	 	22	  
			
	 7.14
	 	 Aggregation of Stock
	  	 	22	  

  
 - iii - 

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is effective as of March 8, 2013 pursuant
to the amendment provisions of Section 7.7 of that certain Investors’ Rights Agreement dated March 30, 2007, as amended (the “Prior Agreement”), by and among Syndax Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), the investors listed on Exhibit A (each individually, an “Investor” and collectively, the “Investors”), Eckard Weber, M.D., Ronald Evans, Ph.D., Peter Ordentlich, Ph.D., Michael Dowries,
Ph.D. and Richard Heyman, Ph.D. (each individually, a “Stockholder” and collectively, the “Stockholders”) and Bayer Schering Pharma AG (formerly known as Schering AG), a corporation organized under the laws of the
Federal Republic of Germany (“Bayer”), and with regard to Bayer, only with respect to Section 2.6, Section 2.7 and any other provisions of this Agreement applicable thereto. 

RECITALS 
 WHEREAS,
certain Investors are purchasing shares of Series B-1 Preferred Stock of the Company (the “Series B-1 Preferred Stock”) pursuant to that certain Series B-1 Preferred Stock Purchase Agreement dated as of even date herewith (the
“Purchase Agreement”). 
 WHEREAS, certain Investors (the “Prior Investors”) are holders of the
Company’s Series A Preferred Stock, which shares may be exchanged for shares of the Company’s Series A-1 Preferred Stock (the “Series A-1 Preferred Stock” and collectively with the Series B-1 Preferred Stock, the
“Prime Preferred Stock”) pursuant to the Purchase Agreement. 
 WHEREAS, the obligations in the Purchase Agreement are
conditioned upon the execution and delivery of this Agreement. 
 WHEREAS, the parties to such Prior Agreement desire to amend and restate
the Prior Agreement and to accept the rights and covenants hereof in lieu of their rights and covenants under the Prior Agreement. 

WHEREAS, the undersigned hold the requisite power and authority pursuant to Section 7.7 of the Prior Agreement to effectuate the
amendment and restatement of the Prior Agreement and enter into this Agreement as set forth herein. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the parties agree as follows: 

SECTION 1 

[Intentionally Omitted.] 

 SECTION 2 

REGISTRATION RIGHTS; 

RESTRICTIONS ON TRANSFERABILITY 

2.1 Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 

“Affiliate” shall mean with respect to any Person, any Person which directly or indirectly through one or more
intermediaries, controls, is controlled by or is under common control with such Person. 
 “Commission” shall mean the
Securities and Exchange Commission or any other federal agency at the time administering the Securities Act. 
 “Conversion
Shares” shall mean the Common Stock issued or issuable upon conversion of the Shares. 
 “Holder” shall mean any
Investor owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 2.14 hereof; provided, however, that with respect to Section 2.6 hereof and other provisions of this
Agreement applicable to a registration pursuant to such section, in addition to the foregoing definition, “Holder” shall also mean the Stockholders and Bayer Schering Pharma AG; provided, further, that with respect to Section 2.7
hereof and other provisions of this Agreement applicable to a registration pursuant to such section, in addition to the foregoing definition, “Holder” shall also mean Bayer Schering Pharma AG. 

“Initiating Holders” shall mean the Investor or transferees of the Investor under Section 2.14 hereof who in the
aggregate are Holders of not less than thirty-five percent (35%) of the outstanding Registrable Securities. 
 “Major
Holder” shall mean the Investor or transferees of the Investor under Section 2.14 hereof who in the aggregate are Holders of not less than five percent (5%) of the fully-diluted shares of the Company on an as-converted
basis (as adjusted for any stock splits, consolidations and the like). 
 “Person” shall mean an individual, a corporation,
a partnership, a trust or unincorporated organization or any other entity or organization. 
 “Preferred Stock” shall mean
the Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock of the Company. 
 The
terms “register,” “registered” and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or
ordering of the effectiveness of such registration statement. 
 “Registrable Securities” means (a) the Conversion
Shares, (b) all shares of Common Stock owned by the Investors, (c) any Common Stock issued (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with
respect to, or in exchange for, or in replacement of, the Common Stock described in clauses (a) or (b) hereof; provided, however, that with respect to Section 2.6 hereof and other provisions’ of this Agreement applicable to a
registration pursuant to such section, in addition to the foregoing definition, “Registrable Securities” shall also mean all shares of Common Stock owned by the Stockholders and Bayer Schering Pharma AG; provided further, that with respect
to Section 2.7 hereof and other provisions of this Agreement applicable to a registration pursuant to such section, 

  
 2 

 
in addition to the foregoing definition, “Registrable Securities” shall also mean all shares of Common Stock owned by Bayer Schering Pharma AG. 

“Registration Expenses” shall mean all reasonable expenses incurred by the Company in complying with Sections 2.5, 2.6 and
2.7 hereof, including, without limitation, all registration, qualification and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, blue sky fees and expenses, the expense of any special audits incident to
or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company) and all reasonable fees and disbursements of (a) one special counsel for all of the
Holders who elect to include their Registrable Securities in any such registration and (b) one special counsel for Bayer if it elects to include its Registrable Securities in any such registration. 

“Restricted Securities” shall mean the securities of the Company required to bear the legend set forth in
Section 2.3 hereof. 
 “Securities Act” shall mean the Securities Act of 1933, as amended, or any similar or
successor federal statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 

“Selling Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the
securities registered by the Holders. 
 “Shares” shall mean shares of the Preferred Stock. 

“Warrant Agreement” shall mean the Warrant Agreement between the Company and Bayer Schering Pharma AG dated March 26,
2007. 
 2.2 Restrictions. The Shares and the Conversion Shares shall not be sold, assigned, transferred or pledged except upon the
conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. The Investor will cause any proposed purchaser, assignee, transferee or pledgee of the Shares and the Conversion
Shares to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 
 2.3
Restrictive Legend. Each certificate representing (a) the Shares, (b) the Conversion Shares, and (c) any other securities issued in respect of the securities referenced in clauses (a) and (b) upon any stock split,
stock dividend, recapitalization, merger, consolidation or similar event, shall (unless otherwise permitted by the provisions of Section 2.4 below) be stamped or otherwise imprinted with a legend in substantially the following form (in
addition to any legend required under applicable state securities laws): 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN
ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THE SHARES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT OR AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT.” 
 “THE SHARES
REPRESENTED BY THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF 

  
 3 

 
AGREEMENTS BETWEEN THE COMPANY AND THE ORIGINAL STOCKHOLDER, COPIES OF WHICH ARE ON FILE WITH THE SECRETARY OF THE COMPANY.” 

Each Holder consents to the Company making a notation on its records and giving instructions to any transfer agent of the Restricted
Securities in order to implement the restrictions on transfer established in this Section 2. 
 2.4 Notice of Proposed
Transfers. The holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions of this Section 2. Prior to any proposed sale, assignment, transfer or pledge
of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transfer, the holder thereof shall give written notice to the Company of such holder’s intention to effect such
transfer, sale, assignment or pledge. Each such notice shall describe the manner and circumstances of the proposed transfer, sale, assignment or pledge in sufficient detail, and shall be accompanied at such holder’s expense by either
(a) an unqualified written opinion of legal counsel who shall, and whose legal opinion shall be, reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transfer of the Restricted Securities may be
effected without registration under the Securities Act, or (b) a “no action” letter from the Commission to the effect that the transfer of such securities without registration will not result in a recommendation by the staff of the
Commission that action be taken with respect thereto, or (c) any other evidence reasonably satisfactory to counsel to the Company, whereupon the holder of such Restricted Securities shall be entitled to transfer such Restricted Securities in
accordance with the terms of the notice delivered by the holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with Rule 144, (y) in any transaction in
which an Investor which is a corporation distributes Restricted Securities solely to its Affiliates for no consideration, or (z) in any transaction in which an Investor which is a partnership distributes Restricted Securities solely to its
partners, limited partners, retired partners, members or retired members for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Section 2. Each certificate evidencing the Restricted
Securities transferred as above provided shall bear, except if such transfer is made pursuant to Rule 144, the appropriate restrictive legends set forth in this Section 2, except that such certificate shall not bear such restrictive
legend if, in the opinion of counsel for such holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act or this Agreement. 

2.5 Requested Registration. 

(a) In case the Company shall receive from Initiating Holders a written request that the Company effect any registration, qualification or
compliance with respect to the Registrable Securities, the Company will: 
 (i) promptly give written notice of the proposed
registration, qualification or compliance to all other Holders; and 
 (ii) as soon as practicable and in any event within
ninety (90) days after receipt of such written request, use its commercially reasonable best efforts to effect such registration, qualification or compliance (including, without limitation, the execution of an undertaking to file post-effective
amendments, appropriate qualification under applicable blue sky or other state securities laws and appropriate compliance with applicable regulations issued under the Securities Act and any other governmental requirements or regulations) as may be
so requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or

  
 4 

 
Holders joining in such request as are specified in a written request received by the Company within twenty (20) days after receipt of the written notice from the Company; provided, however,
that the Company shall not be obligated to take any action to effect any such registration, qualification or compliance pursuant to this Section 2.5: 

(A) In any particular jurisdiction in which the Company would be required to execute a general consent to service of process in
effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(B) Prior to twelve (12) months after the effective date of the Company’s initial public offering; 

(C) After the Company has effected two (2) such registrations pursuant to this subparagraph 2.5(a), such
registration has been declared or ordered effective and the securities offered pursuant to each such registration have been sold; provided that all Registrable Securities requested for inclusion were in fact included in such registration. The
Company shall not be obligated to effect more than two registration statements in any twelve (12) month period; 
 (D)
During the period starting with the date sixty (60) days prior to the Company’s good faith estimate of the date of filing of, and ending on a date one hundred eighty (180) days after the effective date of, a registration initiated by
the Company; provided that the Company is actively employed in good faith in all commercially reasonable best efforts to cause such registration statement to become effective and provided further that the rights of the Initiating Holders to include
Registrable Securities for registration in the Company’s registration shall be governed by Section 2.6 hereof; or 

(E) If such registration, qualification or compliance involves securities with an aggregate value less than Ten Million Dollars
($10,000,000). 
 Subject to the foregoing clauses (A) through (E), the Company shall file a registration statement covering the
Registrable Securities so requested to be registered as soon as practicable after receipt of the request or requests of the Initiating Holders; provided, however, that if (i) in the good faith judgment of the board of directors of the Company
(the “Board”), such registration would be seriously detrimental to the Company and the Board concludes, as a result, that it is essential to defer the filing of such registration statement at such time, and (ii) the Company shall
furnish to such Holders a certificate signed by the President of the Company stating that in the good faith judgment of the Board, it would be seriously detrimental to the Company for such registration statement to be filed in the near future and
that it is, therefore, essential to defer the filing of such registration statement, then the Company shall have the right to defer such filing (except as provided in clause (D) above) for up to two (2) periods of not more than sixty
(60) days each after receipt of the request of the Initiating Holders, and provided further, that the Company shall not defer its obligation in this manner more than once in any twelve-month period. 

(b) Underwriting. In the event that a registration pursuant to Section 2.5 is for a registered public offering involving an
underwriting, the Company shall so advise the Holders as part of the notice given pursuant to Section 2.5(a)(i). The right of any Holder to registration pursuant to Section 2.5 shall be conditioned upon such Holder’s
participation in the underwriting arrangements required by this Section 2.5 and the inclusion of such Holder’s Registrable Securities in the underwriting, to the extent requested and provided herein. 

  
 5 

 The Company shall (together with all Holders proposing to distribute their securities through
such underwriting) enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by a majority in interest of the Initiating Holders (which managing underwriter shall be reasonably acceptable to
the Company). Notwithstanding any other provision of this Section 2.5, if the managing underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten, then the
Company shall so advise all Holders of Registrable Securities and the number of shares of Registrable Securities that may be included in the registration and underwriting shall be allocated among all Holders thereof in proportion, as nearly as
practicable, to the respective amounts of Registrable Securities held by such Holders at the time of filing the registration statement. No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing limitation
shall be included in such registration. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred
(100) shares. 
 If any Holder of Registrable Securities disapproves of the terms of the underwriting, such person may elect to
withdraw therefrom by written notice to the Company, the managing underwriter and the Initiating Holders. The Registrable Securities or other securities so withdrawn shall also be withdrawn from registration, and such Registrable Securities shall
not be transferred in a public distribution prior to ninety (90) days (one hundred eighty (180) days in the case of the Company’s initial public offering) after the date of the final prospectus used in such public offering. 

2.6 Company Registration. 

(a) Notice of Registration. If at any time or from time to time, the Company shall determine to register any of its securities, either
for its own account or the account of a security holder or holders exercising their respective demand registration rights other than (i) a registration relating solely to employee benefit plans, or (ii) a registration relating solely to a
merger, acquisition or exchange, or (iii) a registration relating to convertible debt transaction, the Company will: 

        (i) promptly give to each Holder written notice thereof; and 

        (ii) include in such registration (and any related qualification under blue sky
laws or other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests made within twenty (20) days after receipt of such written notice from the Company by any Holder, but
only to the extent that such inclusion will not diminish the number of securities included by the Company or by Holders of the Company’s securities who have demanded such registration and further subject to the underwriter’s right to limit
the number of securities included in the registration as set forth in Section 2.6(b) below. 
 (b) Underwriting. If the
registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 2.6(a)(i). In such event, the
right of any Holder to registration pursuant to Section 2.6 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of Registrable Securities in the underwriting to the extent provided herein.
All Holders proposing to distribute their securities through such underwriting shall (together with the Company and the other Holders distributing their securities through such underwriting) enter into an underwriting agreement in customary form
with the managing underwriter selected for such underwriting by the Company (or by the Holders who have demanded such registration, as the case may be). Notwithstanding any other provision of this Section 2.6, if the managing underwriter
determines in its sole discretion that marketing factors require a limitation of the number of shares to be underwritten, the managing underwriter may limit the number of Registrable Securities to be included in

  
 6 

 
the registration and underwriting, on a pro rata basis based on the total number of securities (including, without limitation, Registrable Securities owned by each participating Holder) entitled
to be included in such registration; but in no event shall the amount of securities of the participating Holders included in the offering be reduced below thirty percent (30%) of the total amount of securities included in such offering, unless
such offering is the initial public offering of the Company’s securities, in which case the participating Holders may be entirely excluded if the managing underwriter makes the determination described above and no other stockholder’s
securities are included. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder or other holder to the nearest one hundred
(100) shares. If any Holder or other holder disapproves of the terms of any such underwriting, he or she may elect to withdraw therefrom by written notice to the Company and the managing underwriter. Any securities excluded or withdrawn from
such underwriting shall be withdrawn from such registration, and shall not be transferred in a public distribution prior to ninety (90) days (one hundred eighty (180) days in the case of the Company’s initial public offering) after
the date of the final prospectus included in the registration statement relating thereto. 
 (c) Right to Terminate Registration. The
Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.6 prior to the effectiveness of such registration, whether or not any Holder has elected to include securities in such
registration. 
 2.7 Registration on Form S-3. 

(a) If any Holder or Holders of at least twenty percent (20%) of the then outstanding Registrable Securities or Bayer or any assignee
thereof in accordance with the Warrant Agreement requests that the Company file a registration statement on Form S-3 (or any successor form to Form S-3) for a public offering of shares of the Registrable Securities, the reasonably anticipated
aggregate price to the public of which, net of underwriting discounts and commissions, would exceed One Million Dollars ($1,000,000), and the Company is a registrant entitled to use Form S-3 to register the Registrable Securities for such an
offering, the Company shall use its commercially reasonable best efforts to cause such Registrable Securities to be registered for the offering on such form. The Company will (i) promptly give written notice of the proposed registration to all
other Holders, and (ii) as soon as practicable, but in no event later than sixty (60) days following the request, use its commercially reasonable best efforts to effect such registration (including, without limitation, the execution of an
undertaking to file post-effective amendments, appropriate qualification under applicable blue sky or other state securities laws and appropriate compliance with applicable regulations issued under the Securities Act and any other governmental
requirements or regulations) as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the
Registrable Securities of any Holder or Holders joining in such request as are specified in a written request received by the Company within twenty (20) days after receipt of written notice from the Company. The substantive provisions of
Section 2.5(b) shall be applicable to each registration initiated under this Section 2.7. 
 (b) Notwithstanding the
foregoing, the Company shall not be obligated to take any action pursuant to this Section 2.7: (i) in any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting
such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; (ii) in a given twelve month period, after the Company has effected two
(2) such registrations pursuant to subparagraph 2.7(a); or (iii) if the Company shall furnish to such Holders a certificate signed by the President of the Company stating that, in the good faith judgment of the Board, it would be
seriously detrimental to the Company or its stockholders for registration statements to be filed in the near future, then the Company’s obligation to use its commercially reasonable best efforts to file a registration statement shall be

  
 7 

 
deferred for up to two periods of sixty (60) days each, such sixty (60) day periods not to exceed one hundred twenty (120) days from the receipt of the request to file such
registration by such Holder or Holders. The Company shall not defer its obligation in this manner more than once in any twelve-month period. 

2.8 Corporate Transaction. In the event of a Corporate Transaction, the Company shall use reasonable efforts to cause the registration
rights described under this Section 2 to be assumed or equivalent registration rights to be substituted by a successor corporation or a parent or subsidiary of such successor corporation in writing: “Corporate
Transaction” means a sale of all or substantially all of the Company’s assets or a merger, consolidation or other capital reorganization or business combination transaction of the Company with or into another corporation, entity or
person or a sale of capital stock such that the stockholders immediately prior to such sale possess less than fifty percent (50%) of the voting power immediately after such sale; provided however, that (a) the provisions of this
Section 2.8 may be waived by the holders of at least sixty percent (60%) of the then outstanding Registrable Securities and Bayer and (b) the provisions of this Section 2.8 shall not apply in the event of any
Corporate Transaction if all Holders are entitled to receive in exchange for their Registrable Securities consideration consisting solely of (i) cash or (ii) securities of the acquiring corporation which may be immediately sold to the
public without registration under the Securities Act. 
 2.9 Expenses of Registration. All Registration Expenses, including the
reasonable fees and expenses of not more than one special counsel to the Holders, incurred in connection with registrations pursuant to Sections 2.5, 2.6 and 2.7 shall be borne by the Company, provided that the Company shall not be required
to pay the Registration Expenses of any registration proceeding begun pursuant to Section 2.5, the request of which has been subsequently withdrawn by the Initiating Holders. In such case, (i) the Holders of Registrable Securities
to have been registered shall bear all such Registration Expenses pro rata on the basis of the number of shares to have been registered and (ii) the Company shall be deemed not to have effected a registration pursuant to subparagraph
2.5(a) of this Agreement. Notwithstanding the foregoing, however, if at the time of the withdrawal, the Holders have learned of a material adverse change in the condition, business or prospects of the Company from that known to the Holders at
the time of their request, of which the Company had knowledge at the time of the request, then the Holders shall not be required to pay any of such Registration Expenses, all of which shall be borne by the Company. In such case, the Company shall be
deemed not to have effected a registration pursuant to subparagraph 2.5(a) of this Agreement. Unless otherwise stated, all Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the Holders of the
registered securities included in such registration pro rata on the basis of the number of shares so registered. 
 2.10 Registration
Procedures. In the case of each registration, qualification or compliance effected by the Company pursuant to this Section 2, the Company will keep each Holder advised in writing as to the initiation of each registration,
qualification and compliance and as to the completion thereof. The Company will: 
 (a) Prepare and file with the Commission a registration
statement with respect to the Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become and remain effective for at least one hundred twenty (120) days or until the distribution described
in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period that the Holder refrains from selling any securities included
in such registration at the request of the Company or an underwriter of the Common Stock (or any other securities) of the Company and (ii) in the case of any registration on Form S-3 which is intended to be offered on a continuous or delayed
basis, such one hundred twenty (120) day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Securities
Act, permits an offering on a continuous or delayed 

  
 8 

 
basis, and provided further that applicable rules under the Securities Act governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment which
includes (A) any prospectus required by Section 10(a)(3) of the Securities Act or (B) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation
by reference of information required to be included in (a) and (b) above to be contained in periodic reports filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) in the registration statement; 
 (b) Furnish to the Holders participating in such registration and to the underwriters of
the securities being registered such reasonable number of copies of the registration statement and amendments and supplements thereto, preliminary prospectus, final prospectus and such other documents as such underwriters may reasonably request in
order to facilitate the public offering of such securities; 
 (c) Cause all such Registrable Securities registered hereunder to be listed
on each securities exchange on which similar securities issued by the Company are then listed; 
 (d) Notify each Holder of Registrable
Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration
statement, as then in effect, includes an untrue statement of material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; 

(e) Provide transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a CUSIP number
for all such Registrable Securities, in each case not later than effective date of such registration; 
 (f) Prepare and file amendments of
or supplements to the registration statement or prospectus necessary to comply with the Securities Act with respect to disposition of the Registrable Securities covered by such registration statement; 

(g) Use all commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions unless the Company is already qualified to do business or subject to service of process in that jurisdiction; 

(h) Use its best efforts to furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this
Section 2.10, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 2.10, if such securities are being sold through underwriters,
(i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters and
(ii) a letter dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering,
addressed to the underwriters; 
 (i) Make generally available to its security holders, and to deliver to each Holder participating in the
registration statement, an earnings statement of the Company that will satisfy the provisions of Section 11(a) of the Securities Act covering a period of 12 months beginning after the effective 

  
 9 

 
date of such registration statement as soon as reasonably practicable after the termination of such 12-month period; and 

(j) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering. Each Holder and other security holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 

2.11 Indemnification. 

(a) The Company will indemnify each Holder, each of its officers and directors and partners, and each person controlling such Holder within the
meaning of Section 15 of the Securities Act, with respect to which registration, qualification or compliance has been effected pursuant to this Section 2, and each underwriter, if any and each person who controls any underwriter
within the meaning of Section 15 of the Securities Act, against all expenses, claims, losses, damages or liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or
threatened, arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any registration statement, prospectus, offering circular or other document, or any amendment or supplement thereto, incident
to any such registration, qualification or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which
they were made, not misleading, or any violation by the Company of any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities laws applicable to the Company in connection with any such registration,
qualification or compliance, and the Company will reimburse each such Holder, each of its officers and directors, and each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any legal and any
other expenses reasonably incurred in connection with investigating, preparing or defending any such claim, loss, damage, liability or action, as such expenses are incurred,’ provided that the Company will not be liable in any such case to the
extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or omission or alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the
Company by an instrument duly executed by such Holder, controlling person or underwriter and stated to be specifically for use therein. 

(b) Each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such registration,
qualification or compliance is being effected, severally, but not jointly, indemnify the Company, each of its directors and officers, each underwriter, if any, of the Company’s securities covered by such a registration statement, each person
who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, and each other such Holder, each of its officers and directors and each person controlling such Holder within the meaning of Section 15 of
the Securities Act, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement,
prospectus, offering circular or other document, or any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made,
not misleading, and will reimburse the Company, such Holders, such directors, officers, persons, underwriters or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim,
loss, damage, liability or action, as such expenses are incurred, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement,
prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder and stated to be specifically for use therein; provided

  
 10 

 
however that in no event shall any indemnity under this Section 2.11(b) exceed the net proceeds from the offering received by such Holder unless such liability arises out of or is
based upon the willful misconduct by such Holder. 
 (c) If the indemnification provided for in this Section 2.11 is held by a
court of competent jurisdiction to be unavailable to a party entitled to indemnification under this Section 2.11 (the “Indemnified Party”) with respect to any loss, liability, claim, damage or expense referred to herein,
then the party required to provide indemnification (the “Indemnifying Party”), in lieu of indemnifying such Indemnified Party hereunder, instead shall contribute to the amount paid or payable by such Indemnified Party as a result of such
loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions that
resulted in such loss, liability, claim, damage or expense, as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access
to information, and opportunity to correct or prevent such statement or omission. 
 (d) Each Indemnified Party shall give notice to the
Indemnifying Party promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom,
provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may participate in
such defense at such party’s expense; provided, however, that an Indemnified Party (together with all other Indemnified Parties which may be represented without conflict by one counsel) shall have the right to retain its own separate counsel
with the reasonable fees and expenses to be paid by the Indemnifying Party if the Indemnified Party reasonably determines that representation of such Indemnified Party would be appropriate due to actual or potential differing interests between such
Indemnified Party and any other party represented by such counsel in such proceeding. The failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 2 unless
the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend such action. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party,
consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect of such claim or
litigation. 
 2.12 Information by Holder. The Holder or Holders of Registrable Securities included in any registration shall furnish
to the Company such information regarding such Holder or Holders, the Registrable Securities held by them and the distribution proposed by such Holder or Holders as the Company may reasonably request in writing and as shall be required in connection
with any registration, qualification or compliance referred to in this Section 2. 
 2.13 Rule 144 Reporting. With a view
to making available the benefits of certain rules and regulations of the Commission which may at any time permit the sale of the Restricted Securities to the public without registration, after such time as a public market exists for the Common Stock
of the Company, the Company agrees to use its commercially reasonable best efforts to: 

  
 11 

 (a) Make and keep public information available, as those terms are understood and defined in Rule
144 under the Securities Act, at all times after the effective date that the Company becomes subject to the reporting requirements of the Exchange Act; 

(b) File with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the
Exchange Act (at any time after it has become subject to such reporting requirements); and 
 (c) So long as an Investor owns any Restricted
Securities, to furnish to the Investor forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of said Rule 144 (at any time after ninety (90) days after the effective date of the first
registration statement filed by the Company for an offering of its securities to the general public) and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy of the most recent
annual or quarterly report of the Company, and such other reports and documents of the Company and other information in the possession of or reasonably obtainable by the Company as an Investor may reasonably request in availing itself of any rule or
regulation of the Commission allowing an Investor to sell any such securities without registration. 
 2.14 Transfer of Registration
Rights. The rights to cause the Company to register securities granted Investors under Sections 2.5, 2.6 and 2.7 may only be assigned to (i) a transferee or assignee who acquires at least sixty-six percent (66%) of an original
Holder’s Registrable Securities as of the date hereof (subject to adjustment for stock splits, reverse stock splits, stock dividends and other similar transactions), (ii) any other Investor who has such registration rights, (iii) any
assignee of Bayer in accordance with the Warrant Agreement,(iv) any affiliated fund of any Holder that is a partnership or limited liability company, (v) any partner or retired partner of any Holder which is a partnership or member or retired
member of any Holder which is a limited liability company, (vi) any family member or trust for the benefit of any individual Holder or (vii) as provided by restrictions required by law; provided in each case that prompt written notice of
such assignment is given to the Company and such assignee agrees to be bound by the provisions of this Agreement. 
 2.15 Market
Stand-off Agreement. Each Holder agrees in connection with the initial public offering of the Company’s securities (other than a registration of securities in a Rule 145 transaction or with respect to an employee benefit plan) that, upon
request of the Company or the underwriters managing any underwritten offering of the Company’s securities, not to sell, make any short sale of, loan, grant any option for the purchase of, pledge, hypothecate, limit such Holder’s market
risk regarding or otherwise directly or indirectly dispose of any Registrable Securities (other than those included in the registration) or other capital stock of the Company or securities exchangeable or convertible into capital stock of the
Company without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty (180) days from the date of the final prospectus used in such registration) as may be
requested by the Company or such managing underwriters, and to enter into a lock-up agreement in customary form with such underwriters providing for restrictions approved by the Board, provided that all officers and directors of the Company and
holders of at least one percent (1%) of the Company’s voting securities are bound by and have entered into similar agreements. The certificates for the (a) Shares, (b) Conversion Shares, (c) any New Securities and
(d) any other securities issued in respect of the securities referenced in clauses (a), (b) and (c) upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event shall contain, for so long as such
market stand-off provision remains in place, a legend in substantially the following form: 

  
 12 

 “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER
INCLUDING A MARKET STAND-OFF AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL STOCKHOLDER THAT PROHIBITS SALE OR TRANSFER OF SUCH SHARES FOR A PERIOD OF UP TO 180 DAYS FOLLOWING THE DATE OF THE FINAL PROSPECTUS FOR THE INITIAL PUBLIC OFFERING OF THE
ISSUER’S COMMON STOCK. THIS AGREEMENT IS BINDING UPON TRANSFEREES. A COPY OF THE AGREEMENT IS ON FILE WITH THE SECRETARY OF THE ISSUER.” 

2.16 Termination of Rights. The rights of any particular Holder or permitted transferee thereof to cause the Company to register
securities under Sections 2.5, 2.6 and 2.7 shall terminate with respect to such Holder on the earlier of: (a) the date when such Holder can sell all of its Registrable Securities in a single transaction pursuant to Rule 144 of the
Securities Act, (b) the three (3) year anniversary of the effective date of the Company’s initial public offering, or (c) a Liquidating Transaction (as defined in the Company’s Amended and Restated Certificate of
Incorporation, as amended from time to time). 
 SECTION 3 

RIGHT OF FIRST OFFER 
 3.1
Right of First Offer. Subject to the terms and conditions contained in this Section 3, the Company hereby grants to each Investor holding Prime Preferred Stock (each an “RFO Holder”) the right of first offer (the
“Right of First Offer”) to purchase its Pro Rata Portion (as defined below) of any New Securities (as defined in Section 3.2) which the Company may, from time to time, propose to sell and issue. RFO Holder’s
“Pro Rata Portion” for purposes of this Section 3 is equal to (x) the sum of the number of shares of the Company’s Common Stock then held by such RFO Holder and the number of shares of the Company’s Common
Stock issuable upon conversion of the Prime Preferred Stock then held by such RFO Holder divided by (y) the sum of the total number of shares of the Company’s Common Stock then outstanding and the number of shares of the Company’s
Common Stock issuable upon conversion of the then outstanding Prime Preferred Stock, as adjusted (assuming full conversion and exercise of all convertible and exercisable securities). 

3.2 Definition of New Securities. Except as set forth below, “New Securities” shall mean any shares of capital stock
of the Company, including Common Stock and Preferred Stock, whether authorized or not, and rights, options or warrants to purchase said shares of Common Stock or Preferred Stock, and securities of any type whatsoever that are, or may become,
convertible into said shares of Common Stock or Preferred Stock. Notwithstanding the foregoing, “New Securities” does not include: 

(a) the Conversion Shares, 
 (b)
all shares of Common Stock issued or deemed issued to employees or directors of, or consultants or advisors to this corporation, pursuant to the Company’s 2007 Stock Plan, as amended from time to time, and approved by a majority of the board of
directors of this corporation, including a majority of the Preferred Directors (as defined in the Company’s Amended and Restated Certificate of Incorporation, as amended from time to time), 

(c) all shares of Common Stock issued or deemed issued in connection with research and development partnerships, licensing, corporate
partnering, collaborative arrangements or similar transactions 

  
 13 

 
approved by the holders of more than sixty percent (60%) of the outstanding Prime Preferred Stock on an as converted basis, 

(d) all securities issued by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock, 

(e) securities to financial institutions or lessors issued in connection with commercial credit arrangements, equipment financings, or similar
transactions approved by a majority of the Board, including a majority of the Preferred Directors (as defined in the Company’s Amended and Restated Certificate of Incorporation, as amended from time to time), 

(f) capital stock issued in connection with bona fide acquisitions, mergers, consolidations or similar business combinations, provided that
such issuance has been approved by the holders of more than sixty percent (60%) of the outstanding Prime Preferred Stock, 
 (g) Series
A-1 Preferred Stock issued on conversion of the Series A Preferred Stock pursuant to the Purchase Agreement and the Company’s Amended and Restated Certificate of Incorporation, 

(h) Series B-1 Preferred Stock issued on conversion of convertible notes pursuant to the Purchase Agreement and the Company’s Amended and
Restated Certificate of Incorporation, 
 (i) Series B Preferred Stock issued on conversion of convertible notes pursuant to the Purchase
Agreement and the Company’s Sixth Amended and Restated Certificate of Incorporation, as amended from time to time, 
 (j) Series A
Preferred Stock and Series B Preferred Stock issued pursuant to Article V, Section 5(a)(i) of the Company’s Sixth Amended and Restated Certificate of Incorporation, as amended from time to time, 

(k) warrants to purchase Series B-1 Preferred Stock (the “Series B-1 Warrants”) issued pursuant to the Purchase Agreement,

 (l) Series B-1 Preferred Stock issued upon exercise of the Series B-1 Warrants, and any shares of the Company’s capital stock
issuable upon conversion of such shares of capital stock, 
 (m) shares of Common Stock or convertible securities actually issued upon the
exercise of options or shares of Common Stock actually issued upon the conversion or exchange of convertible securities, in each case provided such issuance is pursuant to the terms of such option or convertible security, and 

(n) all securities issued pursuant to a firm commitment, underwritten initial public offering registered under the Securities Act. 

3.3 Notice of Right. In the event the Company proposes to undertake an issuance of New Securities, it shall give each RFO Holder
written notice of its intention, describing the type of New Securities and the price and terms upon which the Company proposes to issue the same. The RFO Holders shall have fifteen (15) days from the date of receipt of any such notice to agree
to purchase shares of such New Securities (up to the amount referred to in Section 3.1), for the price and upon the terms specified in the notice, by giving written notice to the Company and stating therein the quantity of New Securities
to be purchased. If any RFO Holders do not indicate an interest in purchasing any such RFO Holder’s full Pro Rata Portion of such New Securities by the end of the 15-day period, the Company shall give notice of any remaining available New
Securities (the “Overallotment Notice”) to each of the other RFO Holders who has elected to purchase its full 

  
 14 

 
Pro Rata Portion (the “Electing Holders”). Such Overallotment Notice may be made by telephone if confirmed in writing within two (2) days. The Electing Holders shall then
have a right of overallotment such that they shall have ten (10) days from the date such Overallotment Notice was given to indicate an interest to increase the number of shares of New Securities they may purchase pursuant to this
Section 3, in an aggregate amount of up to the number of remaining available shares of New Securities which, if necessary, shall be apportioned pro rata on the basis of the proportion that the number of shares of Prime Preferred Stock
and Common Stock then held by each such Electing Holder who elects to increase the number of shares of New Securities it proposes to purchase bears to the number of shares of Prime Preferred Stock and Common Stock then held by all such Electing
Holders who elect to increase the number of shares of New Securities they propose to purchase. 
 3.4 Exercise of Right. If any RFO
Holder exercises its Right of First Offer hereunder, the closing of the purchase of the New Securities with respect to which such right has been exercised shall take place as soon as practicable after the RFO Holder gives notice of such interest.

 3.5 Lapse and Reinstatement of Right. In the event a RFO Holder fails to exercise the Right of First Offer provided in this
Section 3 in the manner provided above, the Company shall have ninety (90) days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within sixty
(60) days from the date of said agreement) to sell the New Securities not elected to be purchased by such RFO Holder at the price and upon the terms no more favorable to the purchasers of such securities than specified in the Company’s
notice. In the event the Company has not sold the New Securities or entered into an agreement to sell the New Securities within said ninety (90) day period (or sold and issued New Securities in accordance with the foregoing within sixty
(60) days from the date of said agreement), the Company shall not thereafter issue or sell any New Securities without first offering such securities to the RFO Holder in the manner provided above. 

3.6 Transfer of Right of First Offer. The Right of First Offer granted under Section 3 of this Agreement may be assigned to
a transferee or assignee reasonably acceptable to the Company in connection with any transfer of shares of the Company capital stock held by a RFO Holder; provided that (a) such transfer may otherwise be effected in accordance with applicable
securities laws; (b) written notice of such assignment is given to the Company; and (c) the transferee executes a written agreement to be bound by the terms of this Agreement. 

3.7 Rights of Affiliated Investors. For purposes of this Section 3, Investors who are Affiliates of one or more other Investors
shall, at the election of an Investor and one or more such Affiliates, be treated as a group (an “Investor Group”). Members of an Investor Group shall have the right to reallocate the rights granted by this Section 3
among themselves as they determine. 
 3.8 Termination of Right of First Offer. The Right of First Offer granted under this
Section 3 of this Agreement shall terminate and be of no further force or effect upon the effective date of the Company’s initial public offering. In the event any RFO Holder fails to purchase its pro rata share of any New Securities, the
Right of First Offer granted under this Section 3 of this Agreement shall terminate and be of no further force or effect as to such RFO Holder. 

  
 15 

 SECTION 4 

[Intentionally omitted] 

SECTION 5 
 AFFIRMATIVE
COVENANTS OF THE COMPANY 
 The Company hereby covenants and agrees as follows: 

5.1 Financial Information. (a) The Company will furnish to each Major Holder or transferee thereof under Section 2.14
the following reports: As soon as practicable after the end of each fiscal year, and in any event within two hundred seventy (270) days thereafter, consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of such
fiscal year, and consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such year, prepared in accordance with generally accepted accounting principles applied on a consistent basis and setting forth in
each case in comparative form the figures for the previous fiscal year, all in reasonable detail and audited by independent public accountants of national standing selected by the Company and approved by the Board; 

(b) As soon as practicable after the end of each quarter, and in any event within forty-five (45) days thereafter (other than the last
calendar month of each fiscal year), unaudited consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of the quarter, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries,
if any, for such quarter, prepared in accordance with generally accepted accounting principles applied on a consistent basis and setting forth in each case in comparative form the figures for the same quarter one year earlier; provided that
footnotes and schedule disclosure appearing in audited financial statements shall not be required, all in reasonable detail and signed by the principal financial or accounting officer of the Company; 

(c) As soon as practicable after the end of each month, and in any event within thirty (30) days thereafter (other than the last calendar
month of each fiscal year), unaudited consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of the month, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if any,
for such month, prepared in accordance with generally accepted accounting principles applied on a consistent basis and setting forth in each case in comparative form the figures for the same month one year earlier; provided that footnotes and
schedule disclosure appearing in audited financial statements shall not be required, all in reasonable detail and signed by the principal financial or accounting officer of the Company; and 

(d) As soon as practicable, but in any event thirty (30) days prior to the end of each fiscal year, a budget for the next fiscal year,
prepared on a monthly basis, and, as soon as prepared, any other updated or revised budgets for such fiscal year prepared by the Company and approved by the Board. 

5.2 Inspection. The Company shall permit each Major Holder, at such Major Holder’s expense, to visit and inspect the
Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the Major Holder. 

5.3 Confidentiality. Each Major Holder agrees and will cause any representative of such Major Holder to hold in confidence and trust
and not use or disclose any information provided to or learned by it in connection with its rights under this Section 5 that is identified in writing as confidential (the “Confidential Information”), except that such
Major Holder may disclose such information to any partner, member, 

  
 16 

 
subsidiary or parent of such Major Holder for the purpose of evaluating its investment in the Company as long as (a) such partner, member, subsidiary or parent is advised of the
confidentiality provisions of this Section 5.3 and (b) such Major Holder uses its commercially reasonable best efforts to ensure that such partner, member, subsidiary or parent holds such information in confidence and trust and will not
use or disclose any information provided to or learned by it except as required by law. Notwithstanding the above, this Section 5.3 shall not apply to any information which any such Major Holder can prove: 

(a) was in the public domain at the time it was disclosed or has entered the public domain through no fault of such Major Holder; 

(b) was known to such Major Holder, without restriction, at the time of disclosure, as demonstrated by files in existence at the time of
disclosure; 
 (c) is disclosed with the prior written approval of the Company; 

(d) was independently developed by such Major Holder without any use of the Confidential Information and by employees of such Major Holder who
have not had access to the Confidential Information, as demonstrated by files created at the time of such independent development; 
 (e)
becomes known to such Major Holder, without restriction, from a source other than the Company without breach of this Section 5.3 by such Major Holder and otherwise not in violation of the Company’s rights; 

(f) is disclosed generally to third parties by the Company without restrictions similar to those contained in this Section 5.3; or

 (g) is disclosed pursuant to the order or requirement of a court, administrative agency, or other governmental body; provided, however,
that such Major Holder shall provide prompt notice of such court order or requirement to the Company to enable the Company to seek a protective order or otherwise prevent or restrict such disclosure. 

5.4 Patent, Copyright and Nondisclosure Agreements. The Company agrees to require each employee of the Company to execute a Patent,
Copyright and Nondisclosure Agreement and each consultant and advisor of the Company to execute an agreement that provides for confidential treatment of the Company’s proprietary information, substantially in a form reasonably acceptable to the
Board, as a condition of employment or continued employment or engagement, as the case may be, unless otherwise approved by the Board. 

5.5 Stock Vesting. Unless otherwise approved by the Board, the Company agrees that all Common Stock issued to employees, consultants,
advisors, directors and officers in the future shall be subject to a repurchase option which provides that upon termination of the employment of such individual, with or without cause, the Company has the option to repurchase at cost any unvested
shares held by the individual which repurchase option shall lapse twenty-five percent (25%) after one (1) year and the remainder on a monthly basis over the following three (3) year period. No such options or stock grants shall have
acceleration provisions with respect to vesting, unless otherwise approved by a majority of the Board. Notwithstanding the above, this Section 5.4 shall not apply to Stockholders. 

5.6 Qualified Small Business. The Company covenants that so long as any of the shares of Preferred Stock, or the Common Stock into
which such shares are converted, are held by a Holder (in whose hands such shares of Common Stock are eligible to qualify as “qualified small business stock” as defined in 

  
 17 

 
Section 1202(c) of the of the Internal Revenue Code of 1986, as amended (the “Code”) (“Qualified Small Business Stock”), it will (i) comply with any
applicable filing or reporting requirements imposed by the Code on issuers of Qualified Small Business Stock and (ii) execute and deliver to the Holders, from time to time, such forms, documents, schedules and other instruments as may be
reasonably requested thereby to cause the Preferred Stock or the Common Stock into which such shares are converted, to qualify as Qualified Small Business Stock. 

5.7 Insurance. The Company shall within two (2) months of the date hereof obtain from financially sound and reputable insurers
directors’ and officers’ liability insurance on terms consistent with the NVCA VentureInsure product (the “D & O Policy”) in an amount approved by the Board. The Company shall cause to be maintained the D & O
Policy except as otherwise decided in accordance with policies approved by a majority of the Preferred Directors (as defined in the Company’s Amended and Restated Certificate of Incorporation, as amended from time to time). 

5.8 Annual Budget. The Company shall (a) provide to the Board a copy of the proposed Annual Budget for review at least sixty
(60) days prior to the beginning of each fiscal year, and (b) the Company shall obtain the approval of a majority of the Board of the Annual Budget for such fiscal year at least thirty (30) days prior to the commencement of such
fiscal year. 
 5.9 Board Matters. All non-employee directors and official board observers will be reimbursed for their reasonable
out-of-pocket and travel expenses incurred (i) in attending Board meetings (or meetings of committees thereof), (ii) in attending other functions on behalf of the Company, or (iii) in connection with the performance of their duties as
directors. All non-employee directors shall be compensated uniformly. 
 5.10 Management Compensation. The Board of Directors or a
Compensation Committee thereof shall determine the compensation to be paid by the Company to an employee of or consultant to the Company in a managerial position involving compensation of at least $150,000 annually. Any grants of capital stock or
options to employees, officers, directors or consultants of the Company shall be made pursuant to a stock option plan duly adopted by the Board of Directors. 

5.11 Compliance with Laws. The Company shall comply with all applicable laws, rules, regulations and orders, except where noncompliance
would not have a material adverse effect on the business, properties, assets or condition (financial or otherwise) of the Company. The Company shall comply with all applicable federal and state securities laws in connection with the offer, issuance,
sale or redemption of any shares of its capital stock. 
 5.12 Payment of Taxes. The Company will pay and discharge all lawful Taxes
(as defined below) before such Taxes shall become in default and all lawful claims for labor, materials and supplies which, if not paid when due, might become a lien or charge upon its property or any part thereof; provided, however,
that the Company shall not be required to pay and discharge any such Tax, assessment, charge, levy or claim so long as the validity thereof is being contested by or for the Company in good faith by appropriate proceedings and an adequate reserve
therefore has been established on its books. The term “Tax” (and, with correlative meaning, “Taxes”) means all United States federal, state and local, and all foreign, income, profits, franchise, gross receipts,
payroll, transfer, sales, employment, use, property, excise, value added, ad valorem, estimated, stamp, alternative or add-on minimum, recapture, environmental, withholding and any other taxes, charges, duties, impositions or assessments,
together with all interest, penalties, and additions imposed on or with respect to such amounts, or levied, assessed or imposed against the Company. 

5.13 Financings. The Company shall promptly provide to its Board of Directors the details and terms of, and any brochures or investment
memoranda prepared by or for the Company related to, any possible 

  
 18 

 
bone fide and material financing of any nature for the Company, whether initiated by the Company or any other Person. 

5.14 Amended and Restated Voting Agreement. The Company shall cause any Person who acquires (or has the right to acquire) at least one
hundred thousand (100,000) shares of capital stock of the Company to execute a counterpart of the Amended and Restated Voting Agreement of even date herewith, by and among the Company and certain stockholders of the Company (“Voting
Agreement”) (if it is not already a party thereto), such execution indicating such Person’s agreement to become a “Holder” thereunder and to bound by the drag along provisions and related provisions of the Voting Agreement as
of the date of such acquisition. 
 5.15 Termination of Covenants. The covenants set forth in this Section 5 shall terminate on,
and be of no further force or effect at such time as the Company (i) consummates the initial public offering of the Company or (ii) becomes subject to the reporting provisions of the Exchange Act. 

SECTION 6 
 TRANSFERS OF
SECURITIES BY INVESTORS 
 6.1 Notices. If any Investor (the “Transferor”) proposes to sell, assign, hypothecate
or otherwise transfer (a “Transfer”) any securities of the Company owned by such Investor from and after the date of this Agreement, other than pursuant to the provisions of Section 6.6 of this Agreement, the Transferor shall
first give each of the other Investors the right to purchase such securities by delivering to them a written offer which shall state the price and other terms and conditions of the proposed Transfer. If the Transferor proposes to Transfer the
securities for consideration other than solely cash and/or promissory notes, the offer to the Investors shall, to the extent of such consideration, permit each Investor to pay in lieu thereof, cash equal to the fair market value of such
consideration, and the offer shall state the estimate of such fair market value as determined in good faith by the Board. The Transferor shall fix the period of the offer which shall be a minimum of twenty (20) days or such longer period as is
necessary to determine the fair market value of the consideration referred to in the preceding sentence. 
 6.2 Acceptance of Offer.
An Investor may accept an offer (“Purchasing Investor”) only by giving written notice to the Transferor before the offer expires that such Purchasing Investor has accepted the offer to purchase some or all of the securities offered
(the “Accepted Securities”); provided, however, that the maximum number or amount of securities a Purchasing Investor shall be entitled to purchase shall be equal to that number or amount of securities to be transferred multiplied
by a fraction, the numerator of which shall be the number of Conversion Shares held (or deemed to be held) by such Purchasing Investor and the denominator of which shall be the aggregate number of Conversion Shares held (or deemed to be held) by all
Investors, excluding the Transferor’s Conversion Shares. Notwithstanding the foregoing, any Purchasing Investor may, at the time it accepts the offer, subscribe to purchase any or all securities offered which may be available as a result of the
rejection, or partial rejection, of the offer by other Investors, which securities shall be allocated on a pro rata basis among those Purchasing Investors subscribing to purchase them. 

6.3 Allocation of Securities and Payment. Promptly following the expiration of an offer, the Transferor shall allocate the securities
subscribed for among the Purchasing Investors accepting or partially accepting the offer, as set forth in Section 6.2, and shall by written notice (the “Acceptance Notice”) advise all Purchasing Investors of the number
or amount of securities allocated to each of the Purchasing Investors. Within ten (10) days following receipt of the Acceptance Notice, each of the Purchasing Investors shall deliver to the Transferor payment in full for the Accepted Shares
purchased by it against delivery by the Transferor to each Purchasing Investor of a certificate or certificates evidencing the Accepted Securities purchased by it. 

  
 19 

 6.4 Failure to Exercise. To the extent an offer pursuant to Section 6.1 is not
accepted by the other Investors, the Transferor may, for a period of ninety (90) days thereafter, transfer the unaccepted securities, or any of them, upon terms no more favorable than specified in such offer, to any Person or Persons; provided
that such Person or Persons agrees in writing with the Company and the Investors, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of Sections 2.2, 2.3, 2.4, 6 and 7 of this Agreement. 

6.5 Assignment. The right of first refusal set forth in this Section 6 may not be assigned or transferred, except that each
Investor shall have the right to assign its rights to purchase such securities under this Section 6 to any partner, member, retired partner or member or Affiliate of such Investor; provided such partner, member, retired partner or member
or Affiliate agrees in writing with the Company and the Investors, prior to and as a condition precedent to such assignment, to be bound by all of the provisions of Sections 6 and 7 of this Agreement. 

6.6 Permitted Transfers. 

(a) Notwithstanding anything to the contrary contained herein, any Investor which is a partnership or limited liability company may transfer,
without first offering any securities of the Company to any other Investor, all or any of its securities to a partner, limited partner, retired partner, member or retired member of such partnership or to the estate of any such partner, limited
partner, retired partner, member or retired member or transfer by will or intestate succession to his or her spouse or to the siblings, lineal descendants or ancestors of such partner, limited partner, retired partner, member or retired member or
his spouse or to an Affiliate; provided such transferee agrees in writing with the Company and the Investors, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of Sections 6 and 7 of this
Agreement. 
 (b) Notwithstanding anything to the contrary contained herein, any Investor which is a corporation may transfer, without first
offering any securities of the Company to any other Investor, all or any of its securities-to any of its Affiliates, provided such Affiliate agrees in writing with the Company and the Investors, prior to and as a condition precedent to such
Transfer, to be bound by all of the provisions of Sections 6 and 7 of this Agreement. 
 (c) Notwithstanding anything to the
contrary contained herein, any Investor who is an individual may Transfer, without first offering any securities of the Company to any other Investor, all or any of his securities to his spouse or his or his spouse’s siblings, lineal
descendants or ancestors, or to any trust for any of the foregoing or any entity that is an Affiliate of such Investor; provided such transferee agrees in writing with the Company and the Investors, prior to and as a condition precedent to such
Transfer, to be bound by all of the provisions of Sections 6 and 7 of this Agreement. 
 6.7 Drag-Along. Any transferee
of Company securities from an Investor, where such Transfer occurred before the date of the Company’s initial public offering or a Corporate Transaction, shall execute a counterpart of the Voting Agreement (if it is not already a party
thereto), such execution indicating such transferee’s agreement to become a “Holder” thereunder and to bound by the drag along provisions and related provisions of the Voting Agreement as of the date of such transfer. 

6.8 Termination. The right of first refusal granted under this Section 6 shall expire upon the effective date of the
initial public offering of the Company and shall not be applicable to any shares sold pursuant thereto. 

  
 20 

 SECTION 7 

MISCELLANEOUS 
 7.1
Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors, assigns, heirs, executors and administrators and permitted
transferees of the parties hereto. 
 7.2 Third Parties. Nothing in this Agreement, express or implied, is intended to confer upon
any party, other than the parties hereto, and their respective successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

7.3 Governing Law. This Agreement shall be governed by and construed under the laws of the State of Delaware as applied to agreements
entered into and performed in the State of Delaware solely by residents thereof without reference to principles of conflicts of laws or choice of laws. 

7.4 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
 7.5 Notices. Any notice required or permitted by this Agreement shall
be in writing and shall be deemed effectively given the earlier of (i) when received, (ii) when delivered personally, (iii) one (1) business day after being delivered by facsimile (with receipt of appropriate confirmation),
(iv) one (1) business day after being deposited with an overnight courier service or (v) four (4) days after being deposited in the U.S. mail, First Class with postage prepaid, and addressed to the parties at the addresses
provided to the Company (which the Company agrees to disclose to the other parties upon request) or such other address as a party may request by notifying the other in writing. 

7.6 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, portions of such
provisions, or such provisions in their entirety, to the extent necessary, shall be severed from this Agreement, and the balance of this Agreement shall be enforceable in accordance with its terms. 

7.7 Amendment and Waiver. Any provision of this Agreement may be amended or waived with the written consent of the Company and the
Holders of more than sixty percent (60%) of the outstanding shares of the Prime Preferred Stock, voting as a separate class. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each Holder of Registrable
Securities and the Company but in no event shall any amendment or waiver materially increase the obligations of any Holder, except upon the written consent of such Holder. If such amendment or waiver would adversely affect the rights of a specific
series of Preferred Stock in a manner different from the other series of Preferred Stock or Bayer Schering in a manner different from the other Holders, then such amendment or waiver shall require the consent of the Investors holding more than fifty
percent (50%) of such series of Preferred Stock or Bayer Schering, as the case may be. In addition, the Company may waive performance of any obligation owing to it, as to some or all of the Holders of Registrable Securities, or agree to accept
alternatives to such performance, without obtaining the consent of any Holder of Registrable Securities. In the event that an underwriting agreement is entered into between the Company and any Holder, and such underwriting agreement contains terms
differing from this Agreement, as to any such Holder the terms of such underwriting agreement shall govern. 
 7.8 Rights of Holders.
Each Holder of Registrable Securities shall have the right to exercise or refrain from exercising any right or rights that such Holder may have by reason of this Agreement, including, without limitation, the right to consent to the waiver or
modification of any obligation under this Agreement, 

  
 21 

 
and such Holder shall not incur any liability to any other holder of any securities of the Company as a result of exercising or refraining from exercising any such right or rights. 

7.9 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party to this Agreement, upon any
breach or default of the other party, shall impair any such right, power or remedy of such non-breaching party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or
default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of
any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be made in writing and shall be effective only to the extent specifically set forth in such
writing. 
 7.10 Attorneys’ Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this
Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

7.11 Headings. The headings and captions used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs, exhibits and schedules shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits and schedules attached hereto, all of
which are incorporated herein by this reference. 
 7.12 Entire Agreement. This Agreement constitutes the entire understanding and
agreement of the parties with respect to the subject matter hereof and supersedes all prior negotiations, correspondence, agreements, understandings, duties or obligations among the parties with respect to the subject matter hereof. 

7.13 Further Assurances. From and after the date of this Agreement, upon the request of a party, the other parties shall execute and
deliver such instruments, documents or other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement. 

7.14 Aggregation of Stock. All shares of the Preferred Stock held or acquired by affiliated entities or persons shall be aggregated
together for the purpose of determining the availability of any rights under this Agreement. 
 [THE REMAINDER OF THIS PAGE INTENTIONALLY
LEFT BLANK] 

  
 22 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

 COMPANY: 
 SYNDAX PHARMACEUTICALS, INC. 

 

			
	By:	 	 /s/ Arlene M. Morris

		 	Arlene M. Morris,
		 	Chief Executive Officer

  

					
	STOCKHOLDERS:	 		  	ADDRESS:
			
	 /s/ Peter Ordentlich, Ph.D.
	 		  	[REDACTED]
	Peter Ordentlich, Ph.D.	 		  	

 [SIGNATURE PAGE TO INVESTORS RIGHTS AGREEMENT] 

					
	INVESTORS:	  	ADDRESS:
		
	FORWARD VENTURES V, LP	  	For all Forward Ventures entities;
	By:	  	Forward V. Associates, LLC	  	
	Its:	  	General Partner	  	9393 Towne Centre Drive Suite 200
		  		  	San Diego, CA 92121
		  		  	Attn: Ivor Royston, M.D.
			
	By:	  	 /s/ Ivor Royston, M.D.
	  	
	Name:	  	Ivor Royston, M.D.	  	
	Title:	  	Managing Member	  	
		
	FORWARD VENTURES IV, LP	  	
	By:	  	Forward IV Associates, LLC	  	
	Its:	  	General Partner	  	
			
	By:	  	 /s/ Ivor Royston, M.D.
	  	
	Name:	  	Ivor Royston, M.D.	  	
	Title:	  	Managing Member	  	
		
	FORWARD VENTURES IVB, LP	  	
	By:	  	Forward IV Associates, LLC	  	
	Its:	  	General Partner	  	
			
	By:	  	 /s/ Ivor Royston, M.D.
	  	
	Name:	  	Ivor Royston, M.D.	  	
	Title:	  	Managing Member	  	

 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 

					
	INVESTORS:	  	ADDRESS:
		
	DOMAIN PARTNERS VI, L.P.	  	For all Domain entities:
	By:	  	One Palmer Square Associates VI, L.L.C	  	 c/o Domain Associates, L.L.C.

	Its:	  	General Partner	  	 One Palmer Square

		  		  	 Princeton, NJ 08542

		  		  	 Attn: Kathleen K. Schoemaker

			
	By:	  	 /s/ Lisa A. Kraeutler
	  	
		  	Lisa A. Kraeutler,	  	
		  	Attorney-in-fact	  	
	
	DP VI ASSOCIATES, L.P.
	By:	  	One Palmer Square Associates VI, L.L.C.
	Its:	  	General Partner

  

							
		  	By:	  	 /s/ Lisa A. Kraeutler
	  	
		  		  	Lisa A. Kraeutler,	  	
		  		  	Attorney-in-fact	  	

  

							
		
	DOMAIN PARTNERS VIII, L.P.	  	
	By:	  	One Palmer Square Associates VIII, L.L.C.	  	
	Its:	  	General Partner	  	

  

							
		  	By:	  	 /s/ Lisa A. Kraeutler
	  	
		  		  	Lisa A. Kraeutler,	  	
		  		  	Attorney-in-fact	  	

  

							
		
	DP VIII ASSOCIATES, L.P.	  	
	By:	  	One Palmer Square Associates VIII, L.L.C.	  	
	Its:	  	General Partner	  	

  

							
		  	By:	  	 /s/ Lisa A. Kraeutler
	  	
		  		  	Lisa A. Kraeutler,	  	
		  		  	Attorney-in-fact	  	

 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 

					
	INVESTORS:	  	ADDRESS:
		
	MPM BIOVENTURES IV-QP, L.P.	  	For all MPM entities:
		  		  	 200 Clarendon Street, 54th Street

	By:	  	MPM BIOVENTURES IV GP LLC,	  	 Boston, MA 02116

		  	 its General Partner
	  	 Attn: Luke Evnin, Ph.D.

	By:	  	MPM BIOVENTURES IV LLC,	  	
		  	 its Managing Member
	  	

  

					
	By:	  	 /s/ Luke Evnin, Ph.D.
	  	
	Name:	  	Luke Evnin, Ph.D.	  	
	Title:	  	Member	  	
		
	MPM BIOVENTURES IV GMBH & CO.	  	
	BETEILIGUNGS KG	  	
			
	By:	  	MPM BIOVENTURES IV GP LLC,	  	
		  	 in its capacity as the Managing Limited Partner
	  	
	By:	  	MPM BIOVENTURES IV LLC,	  	
		  	 its Managing Member
	  	
			
	By:	  	 /s/ Luke Evnin, Ph.D.
	  	
	Name:	  	Luke Evnin, Ph.D.	  	
	Title:	  	Member	  	
		
	MPM ASSET MANAGEMENT INVESTORS	  	
	BV4 LLC	  	
			
	By:	  	MPM BIOVENTURES IV GP LLC,	  	
		  	 its Manager
	  	
			
	By:	  	 /s/ Luke Evnin, Ph.D.
	  	
	Name:	  	Luke Evnin, Ph.D.	  	
	Title:	  	Member	  	
		
	MPM BIOVENTURES IV STRATEGIC FUND, L.P.	  	
			
	By:	  	MPM BIOVENTURES IV LLC,	  	
		  	 its General Partner
	  	
	By:	  	MPM BIOVENTURES IV LLC,	  	
		  	 its Managing Member
	  	
			
	By:	  	 /s/ Luke Evnin, Ph.D.
	  	
	Name:	  	Luke Evnin, Ph.D.	  	
	Title:	  	Member	  	

 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 

							
	INVESTORS:	 		 	ADDRESS:
			
	PV III CEO FUND, L.P.	 		 	c/o Pappas Ventures
	By:	 	AMP&A Management III, LLC	 		 	P.O. Box 110287
	Its:	 	General Partner	 		 	Research Triangle Park, NC 27709
		 		 		 	Attn: Ford S. Worthy

  

			
	By:	 	 /s/ Ford S. Worthy

	Name:	 	Ford S. Worthy
	Title:	 	Partner and Chief Financial Officer

  

							
	A.M. PAPPAS LIFE SCIENCE VENTURES	 		 	
	By:	 	AMP&A Management III, LLC	 		 	c/o Pappas Ventures
	Its:	 	General Partner	 		 	P.O. Box 110287
		 		 		 	Research Triangle Park, NC 27709
		 		 		 	Attn: Ford S. Worthy
	By:	 	/s/ Ford S.
Worthy                                        
      	 		 	
	Name:	 	Ford S. Worthy	 		 	
	Title:	 	Partner and Chief Financial Officer	 		 	

  

			
	MC LIFE SCIENCE VENTURES, INC.
		
	By:	 	 /s/ Yasuaki Matsuo

	Name:	 	Yasuaki Matsuo
	Title:	 	Executive Vice President

 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 

							
	INVESTORS:	 		 	ADDRESS:
			
	GE CAPITAL EQUITY INVESTMENTS, INC.	 		 	GE Capital Equity Investments, Inc.
		 		 		 	c/o GE Healthcare Financial Services, Inc.
		 		 		 	Two Bethesda Metro Center, Suite 600
		 		 		 	Bethesda, MD 20814
		 		 		 	Attn.: Senior Vice President of Risk - Life Science Finance
	By:	 	 /s/ Jacqueline Kim Blechinger
	 		 	
	Name:	 	Jacqueline Kim Blechinger	 		 	With copies to:
	Its:	 	Duly Authorized Signatory	 		 	GE Healthcare Financial Services, Inc.
		 		 		 	Two Bethesda Metro Center, Suite 600
		 		 		 	Bethesda, MD 20814
		 		 		 	Attn: General Counsel
				
		 		 		 	GE Equity
		 		 		 	201 Merritt 7
		 		 		 	Norwalk, CT 06851
		 		 		 	Attn.: Team Leader – HFS/Syndax

  

	
	 /s/ Ronald Evans, Ph.D.

	Name: Ronald Evans, Ph.D.
	
	 /s/ Roe Reynolds

	Name: Roe Reynolds

 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 

 EXHIBIT A 

SCHEDULE OF INVESTORS 
 A.M. Pappas Life Science
Ventures III, L.P. 
 Avalon Ventures VII, L.P. 
 Domain
Partners VI, L.P. 
 DP VI Associates, L.P. 
 Domain Partners
VIII, L.P. 
 DP VIII Associates, L.P. 
 Forward Ventures IV, LP

 Forward Ventures IVB, LP 
 Forward Ventures V, LP 

MPM Asset Management Investors BV4 LLC 
 MPM BioVentures IV-QP, LP

 MPM BioVentures IV GmbH & Co. Beteiligungs KG 
 MPM
BioVentures IV Strategic Fund, L.P. 
 PV III CEO Fund, L.P. 

MC Life Science Ventures. Inc. 
 GE Capital Equity Investments,
Inc. 
 Ronald Evans, Ph.D. 
 Roe Reynolds

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]